LBRX compared with AVTX: revenue, margins and what each company keeps, and the suppliers and customers both name

LBRXLB Pharmaceuticals Inc

Mkt capRevenueRevenue

AVTXAvalo Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

LBRXLB Pharmaceuticals Inc

AVTXAvalo Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

LBRX

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q3 FY26thin chain±13.5%▲+10.29%×0.76

Q2 FY26—▼−1.13%—

May 13 '26—▲+3.79%—

Q1 FY26—▼−2.81%—

AVTX2 of 4 reports

0 of 2at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±16.8%▼−6.22%×0.37

Q2 FY26±19.6%▼−0.74%×0.04

= impliedLBRX realized, solidAVTX realized, hatchedOne scale, both sides: full bar = 20%× = |realized| ÷ impliedspan: LBRX 224d · AVTX 91dSource: market data

LBRXLB Pharmaceuticals Inc

42.14▲+10.63%· post 41.17

Mkt cap$1.4BRevenue—

AVTXAvalo Therapeutics, Inc.

6.95▲+4.87%· post 6.95

ClosedNov 6 '26

Mkt cap$400.7MRevenue$59,000Q4 FY25

Compare

ClosedNov 6 '26

LBRXLB Pharmaceuticals Inc

AVTXAvalo Therapeutics, Inc.

42.14▲+10.63%post 41.17

Price

6.95▲+4.87%post 6.95

$1.4B

Mkt cap

$400.7M

—

Revenue

$59,000Q4 FY25

LBRX42.14▲+10.63%vsAVTX6.95▲+4.87%ClosedNov 6 '26